| |
FY2004 |
FY2005 |
FY2006 |
FY2007 |
FY2008
(forecasts) |
| Net sales |
862,011 |
879,361 |
920,624 |
972,586 |
962,000 |
| Gross profit |
582,699 |
606,364 |
636,560 |
693,244 |
- |
| % of net sales |
67.6 |
69.0 |
69.1 |
71.3 |
- |
| R&D expenses |
127,622 |
142,076 |
167,945 |
134,463 |
161,000 |
| % of net sales |
14.8 |
16.2 |
18.2 |
13.8 |
16.7 |
| Operating income |
192,239 |
193,020 |
190,514 |
275,904 |
232,000 |
| % of net sales |
22.3 |
22.0 |
20.7 |
28.4 |
24.1 |
| Ordinary income |
194,235 |
202,588 |
197,813 |
284,193 |
246,000 |
| % of net sales |
22.5 |
23.0 |
21.5 |
29.2 |
25.6 |
| Net income |
59,532 |
103,658 |
131,285 |
177,437 |
159,000 |
| % of net sales |
6.9 |
11.8 |
14.3 |
18.2 |
16.5 |
| |
FY2004 |
FY2005 |
FY2006 |
FY2007 |
FY2008
(forecasts) |
Exchange rate
(Yearly average) |
US$ |
108 |
113 |
117 |
114 |
100 |
| Euro |
135 |
138 |
150 |
162 |
150 |
| |
FY2004 |
FY2005 |
FY2006 |
FY2007 |
| Total assets |
1,469,797 |
1,584,522 |
1,470,701 |
1,439,152 |
| Net assets |
1,151,807 |
1,216,897 |
1,098,994 |
1,110,862 |
| Shareholders' equity ratio (%) |
78.4 |
76.8 |
74.7 |
77.1 |
|
(Note) The figures of FY2004 are simple sums of those of former
Yamanouchi and former Fujisawa. |
Disclaimer for Share Price Feed
The past performance of the price of securities must not be relied on as a guide to their future performance. Astellas pharma inc. has not reviewed, is not responsible for, and accepts no liability in respect of, any information or opinion contained on any other website.
For more detail information, please refer to Cautionary Statement.
